Global Companion Animal Drugs Industry Booming: Projected to Reach US$59.2 Billion by 2033 at a 4.4% CAGR | FMI

The Global Companion Animal Drugs Industry is positioned for significant growth, fueled by a rising tide of pet ownership and increasing awareness of pet healthcare. According to a recent analysis, the market is expected to register a steady Compound Annual Growth Rate (CAGR) of 4.4% from 2022 to 2033. This translates to a projected market valuation of US$59.2 billion by 2033, a substantial increase from the US$36.7 billion recorded in 2022.

Companion animals, including beloved pets such as dogs, cats, and horses, receive essential medications designed to safeguard their health and shield them from infections and various health concerns. Companion animal veterinarians play a pivotal role in administering these medications, ensuring the speedy recovery of pets post-surgery, diagnosing and treating ailments, and maintaining their overall well-being.

The significance of companion animal medications extends beyond the well-being of our cherished pets. These drugs also contribute to safeguarding the health of the entire family, protecting them from any potential health risks that pets might pose. In essence, companion animal medications play a vital role in fostering not only the health of our furry friends but also the peace of mind and well-being of those who care for them.

Get a Sample Copy of the Report Using a Work Email To Get a Quick Reply.
https://www.futuremarketinsights.com/reports/sample/rep-gb-1077

Increasing Urbanization and Growing Affluence in Developing Countries to Benefit the Market
Increasing urbanization levels and growing affluence, especially in developing countries, have been driving the adoption of pets, thus leading to increased demand for healthcare products for pets such as companion animal drugs. Continued urbanization has also resulted in the increasing prevalence of various diseases such as allergies, lower appetite, reduced energy, and behavioral anxieties among small companion animals. This has been driving the demand for innovative classes of medicines such as companion animal drugs.

Upcoming Therapeutic Innovations in Pet Care to Aid Market Growth
Besides traditional drugs, animal health companies have also been investing in smart diagnostic care to help prevent diseases before their actual onset. Companies are also trying to develop generic capabilities to demonstrate bioequivalence to reference prescription drugs in the companion animal drugs market, as many key drugs no longer benefit from intellectual property protection. The development of new vaccines and medications for animals is expected to support the growth of the companion animal drugs industry over the forecast period.

Increasing R&D activities and shorter drug-lifecycle are playing an important role in the growth of the companion animal drugs industry. Innovations in companion animal drugs are easier and sustainable for a longer period, while R&D cycle time are shorter (~ three years) in the Companion Animal Healthcare (CAH) industry as compared to human health, ranging between seven and 15 years for other drugs. This increases the return on investment in companion animal drugs and leads to faster profits for the market players.

Grab Your Discount Now Before It Is Gone!
https://www.futuremarketinsights.com/request-discount/rep-gb-1077

Collaborative Ventures to Promote the Global Companion Animal Drugs Industry Growth
Collaborative ventures such as One Health promote the unification of veterinary and medical sciences, leading to better disease surveillance, control, and education, especially for companion animals such as dogs and cats. One Health venture enables the identification of alteration in infection traveling patterns. The patterns are changing mostly in the case of parasites due to changes in climate and increasing host-vector interactions. Some organizations helping in the monitoring of One Health in companion animals are the Companion Animal Parasite Council and European Scientific Counsel Companion Animal Parasites.

Such ventures are expected to complement the growth of the companion animal drugs market.

Low Awareness of Animal Diseases to Hamper the Global Companion Animal Drugs Industry Growth
In many developing countries, people lack awareness regarding certain serious companion animal diseases as opposed to livestock diseases, which are more regularly monitored. This is primarily true about pet vaccinations, which is a mandatory requirement for up to three years. Additionally, parasitic medications for companion animals and livestock are different. Lack of awareness with regards to the differentiation of these medication varieties leads to adverse drug side effects and thus low administration of companion animal medications. Such factors are likely to create a hindrance in the growth of the companion animal drugs market.

Also, the majority of animal healthcare drugs have limited scope for patent extension, primarily due to drug portfolios dominated by drugs that have crossed maturity, which in turn is expected to deter the growth of the companion animal drugs industry over the forecast period.

Key Players in the Global Companion Animal Drugs Industry:

• Zoetis Inc.
• Merck & Co, Ltd.
• Bayer AG
• Elanco
• Boehringer Ingelheim GmbH (Merial)
• Virbac Animal Health
• Ceva Santè Animale

Get Your Customized Impactful Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-1077

Key Segments Covered in Global Companion Animal Drugs Industry Research

Product:

• Antibiotics
• Anti-inflammatory
• Parasiticides
• Heartworm
• Behavioral Products
• Nutritional Products
• Skin Care Products
• Vaccines

Distributional Channel:

• Veterinary Hospitals
• Veterinary Clinics
• Pharmacies and Drug Stores

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube